

Clinical Policy: Avatrombopag (Doptelet)

Reference Number: PA.CP.PHAR.130

Effective Date: 10.17.18 Last Review Date: 10.17.18

Revision Log

Description

Avatrombopag (Doptelet[®]) is a thrombopoietin (TPO) receptor agonist.

FDA Approved Indication(s)

Doptelet is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health & Wellness® that Doptelet is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Thrombocytopenia (must meet all):

- 1. Diagnosis of chronic liver disease;
- 2. Prescribed by or in consultation with a hematologist, hepatologist, or gastroenterologist;
- 3. Recent (within the past 14 days) platelet count is $< 50 \times 10^9/L$;
- 4. Member is scheduled to undergo a medical or dental procedure within the next 30 days;
- 5. Dose does not exceed (a or b):
 - a. Platelet count $< 40 \times 10^9$ /L: 60 mg (3 tablets) per day for a total of 5 days;
 - b. Platelet count of 40 to $< 50 \times 10^9$ /L: 40 mg (2 tablets) per day for a total of 5 days.

Approval duration: 14 days (no more than 5 total days of treatment)

B. Other diagnoses/indications

1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53.

II. Continued Therapy

A. Thrombocytopenia

1. Re-authorization is not permitted. Members must meet the initial approval criteria. **Approval duration: Not applicable**

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Pennsylvania Health and Wellness benefit or member has previously met all initial approval criteria or the Continuity of Care Policy (PA.LTSS.PHAR.01) applies.

Approval duration: Duration of request or 6 months (whichever is less); or

CLINICAL POLICY Avatrombopag



2. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – PA.CP.PMN.53 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key FDA: Food and Drug Administration

TPO: thrombopoietin

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

• Examples of chronic liver disease include: alcoholic liver disease, chronic viral hepatitis (e.g., hepatitis B and C), and nonalcoholic steatohepatitis.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Thrombocytopenia	Platelet count < 40 x 10 ⁹ /L: 60 mg PO QD for a total of 5 days	See regimen
	Platelet count of 40 to < 50 x 10 ⁹ /L: 40 mg PO QD for a total of 5 days	

VI. Product Availability

Tablet: 20 mg

VII. References

- 1. Doptelet Prescribing Information. Durham, NC: Dova Pharmaceuticals, Inc.; May 2018. Available at: https://www.doptelet.com. Accessed May 21, 2018.
- 2. Kumar A, Mhaskar R, Grossman BJ, et al on behalf of the AABB (American Association of Blood Banks) Platelet Transfusion Guidelines Panel. Platelet transfusion: a systematic review of the clinical evidence. Transfusion. 2015; 55: 1116-1127.
- 3. Hayashi H, Beppu T, Shirabe K, Maehara Y, and Baba H. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol. 2014; 20(10): 2595-2605.

CLINICAL POLICY Avatrombopag



Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	10/18	